Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Niacin/Lovastatin Prescribers for Hyperlipidemia(?)

Council Members in this Study Group: 14

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Howard Weintraub, MD
Clinical Director
NYU Medical Center

Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...

Michael Davidson, MD, FACC, Director, Preventive Cardiology, The University of ChicagoMichael Davidson, MD, FACC
Director, Preventive Cardiology
The University of Chicago

Michael Davidson, MD, FACC, is Executive Medical Director at Radiant Research, Director of Preventive Cardiology and Clinical Professor of Medicine at the University of Chicago Pritzker School of Medicine. In addition, he is Founder, President, and Chief Executive Officer of the Chicago Center for Clinical...

Harold Bays, MD, FACP, President and Medical Director, L-MARC Research CenterHarold Bays, MD, FACP
President and Medical Director
L-MARC Research Center

Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...

Hossein Ardehali, MD, PhD, Assistant Professor, Feinberg School of Medicine, Northwestern UniversityHossein Ardehali, MD, PhD
Assistant Professor
Feinberg School of Medicine, Northwestern University

Hossein Ardehali, MD, PhD, is an Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research interest is in the areas of reperfusion injury...

Dan Streja, MD
Clinical Professor of Medicine
University of California, Los Angeles

Dan Streja, MD, is a Clinical Professor of Medicine at the University of California, Los Angeles. He is Co-Director of the Lipid Clinic, the Cardiovascular Prevention Clinic and Diabetes Clinic, and the Divisions of Cardiology and Endocrinology at VA Medical Center of West Los Angeles. Dr. Streja has...

Charles Glueck, MD, Medical Research Director of Cholesterol Center, Jewish HospitalCharles Glueck, MD
Medical Research Director of Cholesterol Center
Jewish Hospital

Charles Glueck, MD, is the Medical Director of Jewish Hospital Cholesterol Center in Cincinnati, Ohio. He has expertise in lipids, lipoproteins, interaction of atherosclerosis and thrombosis, thrombosis, human genetics, epidemiology, obstetrics and gynecology, and hematology. Dr Glueck and colleagues...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
More questions than answers: | 08-06-2008
Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com
Author: GLG Expert Contributor

 Should bisphosphonates be stopped in patients who have been taking them for many years?  Should they be used at all?

Obvious answer - wrong question - NO IMPACT on prescribing | 05-19-2008
Author: GLG Expert Contributor

It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent.  It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.

Questions about bleeding, proper dose and appropriate patient subsets will limit use | 01-25-2008
Author: GLG Expert Contributor

TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin.  Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel). The benefit came at a cost of increased serious bleeding (1.4%, vs....

Outsourcing of compassionate use of drugs? | 01-18-2008
Author: Dan Streja, MD, Clinical Professor of Medicine, University of California, Los Angeles

The Supreme Court has rejected the use of experimental drugs by the dying patients on the grounds that "The framers (of the US constitution) understood that the pursuit of life is an inalienable right that should not be abridged without due process of law." Over the years our patients with terminal...

The impact on Vytorin and zetia sales will be modest reduction after the release of ENHANCE data | 01-14-2008
Analysis of: Schering releases ENHANCE data today | www.tradingmarkets.com
Author: GLG Expert Contributor

Physicians have several possible conclusions that can be taken; These include: - the trial is flawed - the selection of patients with much less CIMT than previous trials such as ASAP and ARBITER flaws the study -  the failure to meet the trial endpoint is only a surrogate and clinical trial data...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Contract Research Organization, Independent/Small
  • Government/Military Hospital or Clinic
  • Other Freestanding Healthcare Facility

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Medical Director
  • Physician - Division Head
  • Director
  • President

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-12-03T13:45:45.387